NS-079

NS-079 is an investigational drug candidate being developed by NeuShen Therapeutics, currently in the discovery and IND-enabling phase. The compound is designed to target neuroplasticity, the brain's inherent ability to reorganize neural pathways and synapses in response to environmental changes, learning, or injury. By modulating neuroplasticity, NS-079 aims to address the underlying pathophysiology of various central nervous system (CNS) disorders, potentially offering therapeutic benefits in conditions where synaptic connectivity and neural adaptation are impaired. As part of NeuShen's CNS-focused pipeline, it represents a novel approach to treating psychiatric and neurological diseases by focusing on structural and functional brain recovery.